Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Aim(s): Evaluation of efficacy of systemic therapy (SSA and target therapy of everolimus (EVE)) in patients with G1-G2 gastrointestinal NETs and pancreatic NETs.
Materials and methods: Analysis of medical treatment of patients diagnosed with advanced well-differentiated G1-G2 NETs with SSA (octreotide, lanreotide) and target therapy (EVE) was carried out. Patients received SSA or EVE both in 1 line of treatment and after prior treatment. The average age of patients was 58,7, and more than half of patients were women (64%). 75% of patients had G2 and 25% had G1. Metastatic liver was the most frequent site (87,5%), 12,5% - retroperitoneal lymph nodes and peritoneum, 12,5% - bones, 1 patient- lungs metastasis. In most patients (75%), marker levels (chromogranin A, 5-HIAA, NSE) were within reference values.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.